By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Biotechnology have been presented. According to news reporting originating in Shijiazhuang, People's Republic of China, by NewsRx journalists, research stated, "The aim of this study was to develop an improved method for labelling ZHER2:342 with Technetium-99m ((99m)Tc) using Gly-(d) Ala-Gly-Gly as a chelator and to evaluate the feasibility of its use for visualization of HER2 expression in vivo. The Affibody® molecule ZHER2:342 was synthesized by Fmoc/tBu solid phase synthesis."
The news reporters obtained a quote from the research from Hebei Medical University, "The chelator, Gly-(d) Ala-Gly-Gly, was introduced by manual synthesis as the N-terminal extensions of ZHER2:342. ZHER2:342 was labelled with (99m)Tc. The labelling efficiency, radiochemical purity and in vitro stability of the labelled molecular probe were analysed by reversed-phase high performance liquid chromatography. Biodistribution and molecular imaging using (99m)Tc-peptide-ZHER2:342 were performed. The molecular probe was successfully synthesized and labelled with (99m)Tc with the labelling efficiency of 98.10 ± 1.73% (n=5). The radiolabelled molecular probe remained highly stable in vitro. The molecular imaging showed high uptake in HER2-expressing SKOV-3 xenografts, whereas the MDA-MB-231 xenografts with low HER2 expression were not clearly imaged at any time after the injection of (99m)Tc-peptide-ZHER2:342. The predominant clearance pathway for (99m)Tc-peptide-ZHER2:342 was through the kidneys. Conculsion: (99m)Tc-peptide-ZHER2:342 using Gly-(d) Ala-Gly-Gly as a chelator is a promising tracer agent with favourable biodistribution and imaging properties that may be developed as a radiopharmaceutical for the detection of HER2-positive malignant tumours."
According to the news reporters, the research concluded: "The (99m)Tc-peptide-ZHER2:342 molecular probe is a promising tracer agent, and the results in this study provide a foundation for future development of protocols for earlier visual detection of cancer in the clinical setting."
For more information on this research see: Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging. The British Journal of Radiology, 2014;87(1033):20130484 (see also Biotechnology).
Our news correspondents report that additional information may be obtained by contacting J.M. Zhang, Dept. of Nuclear Medicine, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, People's Taiwan. Additional authors for this research include X.M. Zhao, S.J. Wang, X.C. Ren, N. Wang, J.Y. Han and L.Z Jia.
Keywords for this news article include: Asia, Biotechnology, Peptides, Proteins, Proteomics, Shijiazhuang, Nanotechnology, Molecular Imaging, Emerging Technologies, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC